http://main.pslgroup.com/news/content.nsf/MedicalNews/852576140048867C852578BF006B70EE
Good news for us with two crosses to bear! 8)
Results, which were presented on June 27, showed that switching patients previously uncontrolled on monotherapy to fixed-dose amlodipine/olmesartan combination therapy allowed 57.9% of patients with type 2 to achieve the primary study endpoint by week 12.
By weeks 12 and 20, 50.0% and 65.3% of patients with type 2 diabetes, respectively, had achieved the cumulative blood pressure goal of <130/80 mm Hg.
Good news for us with two crosses to bear! 8)
Results, which were presented on June 27, showed that switching patients previously uncontrolled on monotherapy to fixed-dose amlodipine/olmesartan combination therapy allowed 57.9% of patients with type 2 to achieve the primary study endpoint by week 12.
By weeks 12 and 20, 50.0% and 65.3% of patients with type 2 diabetes, respectively, had achieved the cumulative blood pressure goal of <130/80 mm Hg.
